Monthly Drifts in Vertex Pharmaceuticals, Inc (VRTX) Stock: A Closer Look

Vertex Pharmaceuticals, Inc [VRTX] stock prices are up 2.70% to $478.96 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The VRTX shares have gain 5.93% over the last week, with a monthly amount glided 6.32%, and seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] stock has seen the most recent analyst activity on May 07, 2025, when Wolfe Research downgraded its rating to a Peer Perform. Previously, Leerink Partners downgraded its rating to Market Perform on May 06, 2025, and kept the price target unchanged to $503. Canaccord Genuity upgraded its rating to a Hold and increased its price target to $424 on February 12, 2025. Canaccord Genuity upgraded its rating to a Hold. Wells Fargo downgraded its rating to Equal Weight for this stock on January 30, 2025, but kept the price target unchanged to $460. In a note dated December 20, 2024, H.C. Wainwright reiterated an Buy rating on this stock and revised its target price from $600 to $535.

The stock price of Vertex Pharmaceuticals, Inc [VRTX] has been fluctuating between $377.85 and $519.88 over the past year. Currently, Wall Street analysts expect the stock to reach $476.33 within the next 12 months. Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] shares were valued at $478.96 at the most recent close of the market. An investor can expect a potential drop of -0.55% based on the average VRTX price forecast.

Analyzing the VRTX fundamentals

The Vertex Pharmaceuticals, Inc [NASDAQ:VRTX] reported sales of 11.04B for trailing twelve months, representing a surge of 2.19%. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -0.07%, Pretax Profit Margin comes in at -0.03%, and Net Profit Margin reading is -0.09%. To continue investigating profitability, this company’s Return on Assets is posted at -0.04, Equity is -0.06 and Total Capital is -0.04. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.1.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 470.72 points at the first support level, and at 462.48 for the second support level. However, for the 1st resistance point, the stock is sitting at 483.27, and for the 2nd resistance point, it is at 487.58.

Ratios To Look Out For

It’s worth pointing out that Vertex Pharmaceuticals, Inc [NASDAQ:VRTX]’s Current Ratio is 2.65. Also, the Quick Ratio is 2.29, while the Cash Ratio stands at 1.24. Considering the valuation of this stock, the price to sales ratio is 11.14, the price to book ratio is 7.46.

Transactions by insiders

Recent insider trading involved LR 2019 Benefit Trust, Director, that happened on May 21 ’25 when 170.0 shares were purchased. Director, SR 2019 Benefit Trust completed a deal on May 21 ’25 to buy 170.0 shares. Meanwhile, EVP, Chief Scientific Officer ALTSHULER DAVID sold 52.0 shares on May 15 ’25.

Related Posts

MZP News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.